Features of hemodynamic and structural parameters of the heart in young people with varying stages of cardiometabolic risk
- Authors: Parve S.D.1, Sineglazova A.V.1
-
Affiliations:
- Kazan State Medical University
- Issue: Vol 103, No 6 (2022)
- Pages: 909-917
- Section: Theoretical and clinical medicine
- URL: https://ogarev-online.ru/kazanmedj/article/view/106656
- DOI: https://doi.org/10.17816/KMJ106656
- ID: 106656
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background. Cardiometabolic diseases are one of the leading causes of disability and mortality worldwide, which justifies the relevance of studying their early manifestations.
Aim. To analyze the hemodynamic and structural echocardiographic parameters of the heart in relation to cardiometabolic risk factors and its staging according to the Cardiometabolic Disease Staging (CMDS) scale in young patients.
Material and methods. 109 patients were examined: 57 males (52.3%) and 52 females (47.7%) aged with a median of 36.1 [32.6–39.2] years without cardiometabolic diseases. The design of the study was a cross-sectional case-control study. The parameters of cardiometabolic risk were assessed with its calculation and assessment taking into account the stage according to the CMDS scale. Echocardiography was performed in M- and B-modes. The data were processed using the SPSS Statistics 23 program. The Mann–Whitney U test, the Kruskal–Wallis test, and the Pearson and Fisher χ2 tests were used. Correlation analysis according to Spearman was carried out.
Results. The first stage of cardiometabolic risk was established in 17 examined patients (15.6%), the rest had stage 2 (n=57; 52.3%) or stage 3 (n=35; 32.1%) of cardiometabolic risk. Deviations from the normal values of hemodynamic echocardiographic parameters were not revealed. The frequency of increase in the index of relative thickness, the thickness of the posterior wall of the left ventricle, the interventricular septum thickness, the myocardium mass of the left ventricle did not differ (p=0.198–0.983). A direct correlation between the left atrial, end-systolic and diastolic volumes, left ventricle wall thickness, and an inverse relationship between the left ventricular ejection fraction and cardiometabolic risk factors was established. At the 3rd stage of cardiometabolic risk, higher values of the left atrial volume (47 [46–49] ml; p=0.005), end-systolic (30.42 [29.23–32.04] ml; p=0.001) and diastolic (79 [78–81] ml; p=0.003) volumes of the left ventricle and lower left ventricular ejection fraction (61 [60.35–62.65] ml; p=0.004) than on the 1st and 2nd stages were diagnosed.
Conclusion. An increase in the cardiometabolic risk is associated with an increase in preload and afterload on the left heart.
Full Text
##article.viewOnOriginalSite##About the authors
Swapnil D. Parve
Kazan State Medical University
Author for correspondence.
Email: drswapnilparve@gmail.com
ORCID iD: 0000-0002-8069-4350
M.D., Assist., Depart. of Primary Care and General Practice
Russian Federation, Kazan, RussiaAlbina V. Sineglazova
Kazan State Medical University
Email: sineglazovaav@mail.ru
ORCID iD: 0000-0002-7951-0040
M.D., D. Sci. (Med.), Assoc. Prof., Head of Depart., Depart. of Primary Care and General Practice
Russian Federation, Kazan, RussiaReferences
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010.
- Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):539–555. doi: 10.1016/j.jacc.2019.11.046.
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425.
- Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014;22(1):110–118. doi: 10.1002/oby.20585.
- Guo F, Garvey WT. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016;24(2):516–525. doi: 10.1002/oby.21344.
- Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):525–538. doi: 10.1016/j.jacc.2019.11.044.
- Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered hemodynamics and end-organ damage in heart failure: Impact on the lung and kidney. Circulation. 2020;142(10):998–1012. doi: 10.1161/CIRCULATIONAHA.119.045409.
- Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in metabolic diseases. JACC Cardiovasc Imaging. 2017;10(6):692–703. doi: 10.1016/j.jcmg.2017.04.001.
- Shlyakhto EV, Nedogoda SV, Konradi AO, Baranova EI, Fomin VV, Vertkin AL, Chumakova GA. The concept of novel national clinical guidelines on obesity. Russian Journal of Cardiology. 2016;(4):7–13. (In Russ.) doi: 10.15829/1560-4071-2016-4-7-13.
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270. doi: 10.1093/ehjci/jev014.
- Vlasov VV. Vvedenie v dokazatelnuyu meditsinu. (Introduction to evidence-based medicine.) Moscow: Media Sphera; 2001. 392 р. (In Russ.)
- González A, Ravassa S, López B, Moreno MU, Beaumont J, San José G, Querejeta R, Bayés-Genís A, Díez J. Myocardial remodeling in hypertension. Hypertension. 2018;72(3):549–558. doi: 10.1161/HYPERTENSIONAHA.118.11125.
- Petersen SE, Sanghvi MM, Aung N, Cooper JA, Paiva JM, Zemrak F, Fung K, Lukaschuk E, Lee AM, Carapella V, Kim YJ, Piechnik SK, Neubauer S. The impact of cardiovascular risk factors on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. PLoS One. 2017;12(10):e0185114. doi: 10.1371/journal.pone.0185114.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.
Supplementary files
